Skip to main content

Advertisement

SpringerLink
Log in

Beta-Blockers and Calcium Channel Blockers: First Line Agents

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Beta-blockers and calcium channel blockers (CCB) are milestones in the treatment of stable coronary ischaemic disease. Their main effects are particularly suited for the management of effort-induced angina because of the reduction of oxygen demand they achieve. The clinical benefits of these drugs are highly reproducible and have been shown to improve overall clinical outcomes. Despite the availability of other, and newer antianginal drugs, treatment guidelines continue to recommend the use of beta-blockers and calcium channel blockers as first line therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology. 2012;122:104–12.

    Article  CAS  PubMed  Google Scholar 

  3. Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010;65:565–70.

    Article  PubMed  Google Scholar 

  4. Kannam JP, Aroesty JM, Gersh BJ. Beta blockers in the management of stable angina pectoris. In: Uptodate. http://www.uptodate.com/. Accessed 15th February 2016.

  5. Reiter MJ. Cardiovascular drug class specificity: Beta-blockers. Prog Cardiovasc Dis. 2004;47:11–33.

    Article  CAS  PubMed  Google Scholar 

  6. Husted SE, Ohman EM. Pharmacological and emerging therapies in the treatment of chronic angina. Lancet. 2015 Aug 15;386(9994):691–701.

  7. Montalescot G, Sechtem U, Achenbach S et al, and The Task Force Members. ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949–3003.

  8. Frishman WH. β-adrenergic blockade in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):310–9.

  9. Chen-Scarabelli C, Saravolatz II L, Murad Y, et al. A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs. 2012;12:391–401.

    CAS  PubMed  Google Scholar 

  10. Frishman WH, Saunders E. Adrenergic blockers. J Clin Hypertens (Greenwich). 2011;13:649–53.

    Article  CAS  Google Scholar 

  11. Frohlich ED, Tarazi RC, Dustan HP. Peripheral arterial insufficiency. A complication of beta-adrenergic blocking therapy. JAMA. 1969;208(13):2471–2.

    Article  CAS  PubMed  Google Scholar 

  12. Salem SA, McDevitt DG. Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther. 1983;33(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  13. Frishman WH, Clark A, Johnson B. Effects of cardiovascular drugs on plasma lipids and lipoproteins. In: Frishman WH, Sonnenblick EH, editors. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997. p. 1515–59.

    Google Scholar 

  14. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of anti- hypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.

    Article  CAS  PubMed  Google Scholar 

  15. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369–79.

    Article  PubMed  Google Scholar 

  16. Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med. 2002 Mar;112(4):269–74.

  17. Black JW, Crowther AF, Shanks RG, Smith LH, Dornhorst AC. A new adrenergic betareceptor antagonist. Lancet. 1964;1:1080–1.

  18. Hamer J, Grandjean T, Melendez L, Sowton GE. Effect of propranolol (Inderal) in angina pectoris: preliminary report. Br Med J. 1964;19:720–3.

    Article  Google Scholar 

  19. Warren SG, Brewer DL, Orgain ES. Long-term propranolol therapy for angina pectoris. Am J Cardiol. 1976 Mar 4;37(3):420–6.

  20. Hernández-Cañero A, González A, Cardonne A, Pérez-Medina T, Garcia-Barreto D. Effect of atenolol in angina pectoris of effort. Cor Vasa. 1972;20:99–103.

    PubMed  Google Scholar 

  21. Narahara KA. Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris. Betaxolol Investigators Group Am J Cardiol. 1990;65:577–82.

    Article  CAS  Google Scholar 

  22. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol, a randomized controlled trial. Vasc Health Risk Manag. 2007;3:235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ryden L. Efficacy of epanolol versus metoprolol in angina pectoris, report from a Swedish multicentre study of exercise tolerance. J Intern Med. 1992;231:7–11.

    Article  CAS  PubMed  Google Scholar 

  24. Boberg J, Larsen FF, Pehrsson SK. The effects of beta blockade with (epanolol) and without (atenolol) intrinsic sympathomimetic activity instable angina pectoris. The Visacor Study Group Clin Cardiol. 1992;15:591–5.

    Article  CAS  Google Scholar 

  25. Kaski JC, Rodriguez-Plaza L, Brown J, Maseri A. Efficacy of carvedilol (BM14, 190), a new beta-blocking drug with vasodilating properties, in exercise-induced ischemia. Am J Cardiol. 1985;56:35–40.

    Article  CAS  PubMed  Google Scholar 

  26. Pepine CJ, Cohn PF, Deedwania PC, Gibson RS, Handberg E, Hill JA, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The atenolol silent ischemia study (ASIST). Circulation. 1994;90:762–8.

    Article  CAS  PubMed  Google Scholar 

  27. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J. 1988 Jan;9(1):8–16.

  28. Dargie HJ, Ford I, Fox KM. Total ischaemic burden European trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET study group. Eur Heart J. 1996 Jan;17(1):104–12.

  29. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The angina prognosis study in Stockholm (APSIS). Eur Heart J. 1996;17:76–81.

    Article  CAS  PubMed  Google Scholar 

  30. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999 May 26;281(20):1927–36.

  31. Russek HI. Propranolol and isosorbide dinitrate synergism in angina pectoris. Am J Cardiol. 1968 Jan;21(1):44–54.

  32. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Jul;22(7):837–48.

  33. Frishman WH, Sica DA. Calcium channel blockers. In: Frishman WH, Sonnenblick EH, Sica DA, editors. Cardiovascular Pharmacotherapeutics. New York: McGraw-Hill; 2003.

    Google Scholar 

  34. Ong P, Sechtem U. Calcium Channel blockers. In: Avanzas P, Kaski JC, editors. Pharmacological treatment of chronic stable angina pectoris, current cardiovascular therapy. Switzerland: Springer International; 2015.

    Google Scholar 

  35. Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. Am J Cardiol. 1979;44:832–8.

    Article  CAS  PubMed  Google Scholar 

  36. Henry PD, Shuchleib R, Clark RE, Perez JE. Effect of nifedipine on myocardial ischemia. Am J Cardiol. 1979;44:817–24.

    Article  CAS  PubMed  Google Scholar 

  37. Stone PH. Calcium antagonists for Prinzmetal’s variant angina, unstable angina and silent myocardial ischemia: therapeutic tool and probe for identification of pathophysiologic mechanisms. Am J Cardiol. 1987;59:101B–15B.

    Article  CAS  PubMed  Google Scholar 

  38. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propanolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina: differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation. 1990;82:1962–72.

    Article  CAS  PubMed  Google Scholar 

  39. Antman E, Muller J, Goldberg S, et al. Nifedipine therapy for coronary-artery spasm: experience in 127 patients. N Engl J Med. 1980;302:1269–73.

    Article  CAS  PubMed  Google Scholar 

  40. Ezekowitz MD, Hossack K, Mehta JL, et al. Amlodipine in chronic stable angina: results of a multicenter double-blind crossover trial. Am Heart J. 1995;129:527–35.

    Article  CAS  PubMed  Google Scholar 

  41. Boman K, Saetre H, Karlsson LG, et al. Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. Eur J Clin Pharmacol. 1995;49:27–30.

    Article  CAS  PubMed  Google Scholar 

  42. Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs. 1996;51:792–819.

    Article  CAS  PubMed  Google Scholar 

  43. Cohn PF. Concomitant use of nitrates, calcium channel blockers, and beta-blockers for optimal antianginal therapy. Clin Cardiol. 1994;17:415–21.

    Article  CAS  PubMed  Google Scholar 

  44. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27:311.

    Article  CAS  PubMed  Google Scholar 

  45. Poole-Wilson PA, Lubsen J, Kirwan BA et al, On behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857.

  46. Taylor SH. Usefulness of amlodipine for angina pectoris. Am J Cardiol. 1994;73:28A.

    Article  CAS  PubMed  Google Scholar 

  47. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004 Nov 10;292(18):2217–25.

  48. Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med. 1981;71:443.

    Article  CAS  PubMed  Google Scholar 

  49. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-Trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003 Dec 3;290(21):2805–16.

  50. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ, INVEST Study Group. A study of antihypertensive drugs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the international verapamil SR-Trandolapril study (INVEST). Psychosom Med. 2005 May-Jun;67(3):398–406.

  51. Hossack KF, Pool PE, Steele P, et al. Efficacy of diltiazem in angina on effort: a multicenter trial. Am J Cardiol. 1982;49:567.

    Article  CAS  PubMed  Google Scholar 

  52. Strauss WE, McIntyre KM, Parisi AF, Shapiro W. Safety and efficacy of diltiazem hydrochloride for the treatment of stable angina pectoris: report of a cooperative clinical trial. Am J Cardiol. 1982;49:560.

    Article  CAS  PubMed  Google Scholar 

  53. Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. Clin Cardiol. 1991 Apr;14(4):314–6.

  54. Leon MB, Rosing DR, Bonow RO, Epstein SE. Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris. Am J Cardiol. 1985 Jan 25;55(3):69B–80B.

  55. Dunselman PH, van Kempen LH, Bouwens LH, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol. 1998;81:128.

    Article  CAS  PubMed  Google Scholar 

  56. Beltrame JF, Crea F, Kaski JC et al. 2015 Aug International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 4. pii: ehv351. Epub ahead of print.

  57. Chahine RA. The calcium antagonists in vasospastic angina. J Cardiovasc Pharmacol. 1991;17(Suppl 1):S40–2.

    Article  PubMed  Google Scholar 

  58. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. REACH registry investigators. β-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3;308(13):1340–9.

  59. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872–81.

Download references

Author information

Authors and Affiliations

  1. Área del Corazón, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, 33011, Oviedo, Asturias, Spain

    Isaac Pascual, Cesar Moris & Pablo Avanzas

Authors
  1. Isaac Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cesar Moris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo Avanzas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Avanzas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pascual, I., Moris, C. & Avanzas, P. Beta-Blockers and Calcium Channel Blockers: First Line Agents. Cardiovasc Drugs Ther 30, 357–365 (2016). https://doi.org/10.1007/s10557-016-6682-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-016-6682-1

Keywords

Search

Navigation